AGAM
DFTX

Audent Global Asset Management’s Definium Therapeutics DFTX Stock Holding History

Audent Global Asset Management’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-5,200
Closed -$50K – 47
2022
Q2 		$50K Hold
5,200
– – 0.03% 45
2022
Q1 		$87K Hold
5,200
– – 0.05% 48
2021
Q4 		$108K Buy
+5,200
New +$166K 0.05% 46

Other funds holding DFTX

DCI
Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return
MFG
Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
BB
Busey Bank Urbana, Illinois $3.68B AUM 26.6% 1-Year Est. Return
EAM
Empery Asset Management New York $83M AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Audent Global Asset Management's DFTX Position: Q3 2022 in Review

Audent Global Asset Management sold out of Definium Therapeutics (DFTX) in Q3 2022, closing a stake of 5,200 shares — an estimated $50K sold.

Audent Global Asset Management first reported a position in DFTX in Q4 2021 and held it in 3 quarters. The position peaked at $108K in Q4 2021. 101 funds tracked by Wall St. Rank hold DFTX as of Q3 2022.

  • Audent Global Asset Management reported no remaining Definium Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Audent Global Asset Management sold 5,200 Definium Therapeutics shares in Q3 2022, an estimated $50K.
  • Audent Global Asset Management first reported a position in Definium Therapeutics in Q4 2021 and held it in 3 quarters.
  • Audent Global Asset Management's Definium Therapeutics position peaked at $108K in Q4 2021.
  • 101 funds tracked by Wall St. Rank held Definium Therapeutics as of Q3 2022.

Based on Audent Global Asset Management's 13F filing for Q3 2022, filed 14 Nov 2022.